It seems strange that in this day and age there are more than 7,000 rare diseases.
-
Biotechnology provides new solutions for the diagnosis and treatment of diseases.Biotechnology uses biological systems, living organisms and derivatives capable of offering new, more complex and effective treatments.
-
The power of the biotechnology industry in the pharmaceutical sector.The products of biotechnology companies currently account for seven out of ten of the world's best-selling medicines.
-
A population that is increasing in number and age.A trend that continues to grow and that will require a greater number of diagnoses and medical treatments.
-
An increasingly ageing population.Projections indicate that by 2050, the population over 60 years of age will have doubled.
-
The older the population, the higher the consumption of medicines.From the age of 60, the consumption of medicines is 2.5 times greater than that of a young person and even more relevant: from the age of 80, the figure is multiplied by nine.
Projection of the world population over 60 years of age.
Health spending increases with age
-
It is estimated that 300 million people in the world are affected by the 7,000 rare diseases that have been identified.But the most significant fact is: 95% of these diseases do not have an approved drug for their treatment.
-
54.5 million people currently suffer from arthritis.One in four Americans suffers from this disease, almost the equivalent of the entire population residing in Italy.
Investment in health: a fundamental aspect for the economic and social growth of the countries.
-
The higher the GDP, the higher the investment in health.For example, In the USA , per capita spending on health is 17 times greater than in China, although these differences will tend to narrow as the countries' per capita income increases.
-
The engine of emerging countries.Globally, spending in the biotech sector is expected to grow by 10% per year until 2026.
The investment universe is based around globally listed companies focused on the biotech sector and offering exposure to cutting-edge biotech companies working on drug development and molecular diagnostics.
-
Phase II drug development.That is, those that begin to show the first signs of efficiency in humans before taking a position in companies.
-
Equipment and supplies.Within the industry, investments are made in medical equipment and supply companies, medical service providers, pharmaceuticals, and tools and services for the health sciences.
What do the experts think?
- It's a sector that is less sensitive to economic cycles because healthcare isn't correlated with the market.
- It has the ability to set prices and therefore adapts better to inflationary periods like the present one.
- It's market that is currently trading well below its historical valuations and the general market.
-
See summary in Spanish of the rights of investors of the Bellevue Obesity Solutions Fund
-
See summary in Spanish of the rights of investors of the Candriam Biotechnology Fund
-
See summary in Spanish of the rights of investors of the Pictet Biotech Fund
-
SEE SUMMARY IN SPANISH OF THE RIGHTS OF INVESTORS IN THE BANKINTER PLATEA MEGATENDENCIAS FUND
-
Legal text, Note: 1 Investment funds: The key investor information document, prospectus and all other legal documents related to Bankinter's collective investment institutions are available in Spanish at any of our branches, on the Bankinter website (www.bankinter.com) and on the website of the Spanish National Securities Market Commission (CNMV) (www.cnmv.es).
-
This is an advertising communication. Please refer to the UCITS prospectus and key investor information document before making a final investment decision. The fund managers may decide to stop marketing the funds in the situations provided for in applicable legislation, in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.
-
The Key Investor Information Document and the prospectus are available on the website of the investment managers: Bankinter.com; Candriam , Waystone – Services to the Asset Management Industry , Pictet Spain | Independent investment company
More information on this product can be found on the websites of the investment managers: Bankinter.com; Candriam , Waystone – Services to the Asset Management Industry , Pictet Spain | Independent investment company -
The CANDRIAM BIOTECHNOLOGY Fund is a sub-fund of Candriam Equities L SICAV, authorised in Luxembourg, regulated by the Commissión de Surveillance du Secteur Financier (CSSF) and registered with the CNMV under number 233.
-
The PICTET BIOTECH Fund is a sub-fund of Pictet AM, authorised in Luxembourg, regulated by the Commissión de Surveillance du Secteur Financier (CSSF) and registered with the CNMV under number 194.
-
The Bellevue Obesity Solutions Fund is a sub-fund of Bellevue Funds (Lux), authorised in Luxembourg, regulated by the Commissión de Surveillance du Secteur Financier (CSSF) and registered with the CNMV under number 938.
-
The BANKINTER PLATEA MEGATENDENCIAS fund is a fund from Bankinter Gestión de Activos, S.A., SGIIC authorised in Spain and regulated by the CNMV, with which it is registered as number 5408.
-
The CIS promotes environmental, social and governance (ESG) criteria under Article 8 of Regulation (EU) 2019/2088 on the disclosure of information related to sustainability in the financial services sector, also known by the English acronym SFDR, and is subject to sustainability risk, as defined in the risk profile. Decisions to invest in this fund must consider all of the characteristics and objectives of the fund.
-
See information on aspects related to sustainability: Sustainable and responsible investing | Candriam, Sustainability - Pictet Asset Management (am.pictet), Environmental, social and corporate governance - Waystone; Sustainability Plan | Bankinter Corporate Website.